Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2'-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 6, 1998, Pages 457-463

  Elliott, M J ^a   Stribinskicne, L ^a   Lock, R B ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

Apoposis; Bcl 2; Clonogenic survival; Drug resistance; Human tumor cells

Indexed keywords

DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; ONCOPROTEIN; PROTEIN BCL 2; STAUROSPORINE;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG RESISTANCE; EPITHELIUM TUMOR; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DNA FRAGMENTATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLOXURIDINE; HELA CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAUROSPORINE;

EID: 0031936648     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050767     Document Type: Article

References (27)

1. Alderson LM, Castleberg RL, Harsh GR IV, Louis DN, Henson JW (1995) Human gliomas with-wild-type p53 express bcl-2. Cancer Res 55: 999
2. Berger NA, Chatterjee S, Schmotzer JA, Helms SR (1991) Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA 88: 8740
3. Chen AY, Liu LF (1994) DNA topoisomerases: essential enzymes and lethal tagets. Annu Rev Pharmacol Toxicol 34: 191
4. Curtin NJ, Harris AL, Aherne GW (1991) Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation. DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 51: 2346
5. DeVita VTJ, Hellman S, Rosenberg SA (1993) Cancer: principles and practice of oncology, 4th edn. J.B. Lippincott Co., Philadelphia
6. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA (1993) bcl-2 Modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321
7. Gasparini G, Barbareschi M, Doglioni C, Raima PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL (1995) Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1: 189
8. Gorczyca W, Gong J, Darzynkiewicz Z (1993) Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53: 1945
9. Han J, Dionne CA, Kedersha NL, Goldmacher VS (1997) p53 Status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in Rat-1 fibroblasts constitutively expressing c-myc. Cancer Res 57: 176
10. Hickman JA (1992) Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121
11. Hoppe-Seyler F, Butz K (1993) Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 67: 3111
12. Jacobson MD, Burne JF, King MP, Miyashita Y, Reed JC, Raff MC (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365
13. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294
14. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K (1995) Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177: 49
15. Lock RB, Stribinskiene L (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006
16. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ (1994) Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 54: 4933
17. Lock RB, Thompson BS, Sullivan DM, Stribinskiene L (1997) Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation. Cancer Chemother Pharmacol 39: 399
18. Meikrantz W, Gisselbrecht S, Tarn SW, Schlegel R (1994) Activation of cyclin A-dependent kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754
19. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690
20. Reed JC (1995) BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451
21. Shibuya ML, Ueno AM, Vannais DB, Craven PA, Waldren CA (1994) Megabase pair deletions in mutant mammalian cells following exposure to amsacrine, an inhibitor of DNA topoisomerase II. Cancer Res 54: 1092
22. Silvestrini R, Veneroni S, Daidone MG, Benini E, Borscchi P (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer in patients. J Natl Cancer Inst 86: 499
23. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604
24. Singh B, Gupta RS (1983) Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res 43: 577
25. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214
26. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386
27. Yin DX, Schimke RT (1995) BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922